Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12657618 | 0.86 | TDP1 (0.38) | TDP1CRBNLMNAALOX15BLM | |
| SCHEMBL2297127 | 0.80 | CRBN (0.38) | TDP1CRBNLMNAALOX15BLM | |
| SCHEMBL24548415 | 0.80 | CRBN (0.38) | CRBNLMNAALOX15BLMPMP22 | |
| Methacrylic Acid SCHEMBL30127634 | 0.79 | TDP1 (0.37) | TDP1CRBN | |
| SCHEMBL26884 | 0.78 | CRBN (0.36) | CRBNLMNAALOX15BLMPMP22 | |
| SCHEMBL129220 | 0.78 | CRBN (0.36) | CRBNLMNAALOX15BLMPMP22 | |
| SCHEMBL27927208 | 0.74 | ALDH1A1 (0.37) | CRBNLMNAALOX15BLMPMP22 | |
| SCHEMBL22084139 | 0.74 | — | — | |
| SCHEMBL28050835 | 0.73 | — | — | |
| SCHEMBL22050835 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | MAPT, GAP43, RNMT | TDP1 127/4885CRBN 2579/4885LMNA 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.